



Invesco Global Health Care Innovation Fund

30 September 2020

Morningstar Rating™*



Important Information

- Until 28 July 2020, the Fund invests primarily in equity and equity related securities of healthcare companies throughout the world. From 29 July 2020, the Fund invests primarily in equity and equity related securities of innovative healthcare companies throughout the world.
- Investors should note the risk of investing in healthcare companies, concentration risk of investing in healthcare companies throughout the world, currency exchange risk, equities risk, volatility risk, and general investment risk.
- Financial derivative instruments (FDI) may be used for efficient portfolio management purposes or to hedge or reduce the overall risk of investments. Risks associated with FDI include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. The leverage element/component of a FDI can result in a loss significantly greater than the amount invested in the FDI by the Fund. Exposure to FDI may lead to a high risk of significant loss by the Fund.
- The value of the Fund can be volatile and could go down substantially.
- Investors should not base their investment decision on this material alone.

Objectives and investment strategy

The Fund aims to achieve long-term capital growth. The Fund seeks to achieve its objective by investing primarily in equity and equity related securities of innovative healthcare companies throughout the world.

Key facts


Fund manager	Henry Wu
Share class launch date	
A (USD)-AD Shares	10/9/18
Legal Status	Luxembourg SICAV with UCITS status
Share class currency	USD
Fund Size	USD 343.92 mn
Initial Charge (up to)	5.00%
Annual Management Fee	1.5%
Reference Benchmark	MSCI World Health Care ND

References	IVRS Code	Bloomberg code	ISIN code
A(USD)-AD Shares	601	IVGHCAD LX	LU1775982595

3 year characteristics*

	A (USD)-AD Shares
Volatility	17.65
Volatility is measured by the standard deviation of the fund, based on its annual rates of return over the past 3 years in base currency of the fund.	

Indexed performance*



	Cumulative performance*				Calendar year performance*				
%	YTD	1 year	3 years	5 years	2015	2016	2017	2018	2019
A (USD)-AD Shares	0.49	20.06	26.14	37.45	1.02	-13.51	14.37	-3.09	31.23
Benchmark	6.26	20.81	35.42	60.33	6.60	-6.81	19.80	2.51	23.24

#The historical performance shown in the chart above up to 7th September 2018 has been simulated based on the performance of a share class with the same features (e.g. investment objectives and strategy, risk profiles and fee structure) of another fund, which was merged into the Fund on that date.

Distribution information

(Aims to pay dividend on monthly/quarterly/semi-annual/ annual basis. Dividend is not guaranteed.)

	Intended frequency	Record date	Amount/Share	Annualized dividend (%)
A (USD)-AD Shares	Annual	28/02/20	0.0000	0.00%

Annualized dividend (%) = (Amount/Share X Frequency) ÷ Price on record date. Upon dividend distribution, the Fund's net asset value may fall on the ex-dividend date. For Frequency, Monthly = 12; Quarterly = 4; Semi-Annually = 2; Annually = 1. All distributions below USD 50 in value (or its equivalent) will be automatically applied in the purchase of further shares of the same class. Positive distribution yield does not imply a positive return.

Holding	(total holdings: 83)						
Top 10 holdings		%	Geographical weightings	%	Sector weightings		%
Thermo Fisher Scientific		5.9	United States	74.7	Pharmaceuticals		32.1
UnitedHealth		4.8	Switzerland	6.9	Health Care Equipment & Supplies		21.8
AstraZeneca		4.2	United Kingdom	4.5	Biotechnology		15.8
Johnson & Johnson		4.1	Denmark	2.9	Health Care Providers & Services		14.9
Novartis ADR		4.0	France	2.7	Life Sciences Tools & Services		9.0
Medtronic		3.8	Brazil	1.9	Health Care Technology		3.1
Abbott Laboratories		3.0	Netherlands	1.8	Food & Staples Retailing		0.4
Sanofi ADR		2.7	China	0.8	Household Products		0.3
Eli Lilly		2.6	Others	1.4	Software		0.1
Vertex Pharmaceuticals		2.6	Cash	2.4	Cash		2.4

Important Information

Since 29 July 2020, the Invesco Global Health Care Fund has been re-named the Invesco Global Health Care Innovation Fund. In addition, the management fee of the fund was reduced to 1.5% from 2%. Derivatives and cash equivalent instruments are excluded in the calculation of Top 10 holdings. Investment involves risks. Past performance is not indicative of future performance. Investors should read the relevant prospectus for details, including the risk factors and product features. This material has not been reviewed by the Securities and Futures Commission and is issued by Invesco Hong Kong Limited (景順投資管理有限公司). ©2020 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is provided for reference purposes only. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Asset allocation data is derived by Morningstar using full holdings data provided by Invesco. Morningstar Licensed Tools and Content powered by Interactive Data Managed Solutions. All data is as of the date of this document and sourced from Invesco unless otherwise stated. Portfolio weightings and allocations are subject to change. The weightings for each breakdown are rounded to the nearest tenth or hundredth of a percent; therefore, the aggregate weights for each breakdown may not equal 100%.

*Source: Data as of the date of this document. Performance of the share class(es) and Morningstar rating are sourced from ©2020 Morningstar. Index performance is sourced from Invesco. Morningstar rating (if applicable) is given to the share class as shown in the Indexed performance chart. Performance of the share class(es) is calculated based on NAV to NAV, gross income re-invested in share class currency.

Prospectus and Financial Reports



KFS of the fund



202008(AP11199)